C. Ustun, J. Miller, D. Munn, D. Weisdorf, and B. Blazar, Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?, Blood, vol.118, issue.19, pp.5084-95, 2011.
DOI : 10.1182/blood-2011-07-365817

C. Fauriat, A. Moretta, D. Olive, and R. Costello, Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients, Blood, vol.106, issue.6, pp.2186-2194, 2005.
DOI : 10.1182/blood-2005-03-1270

F. Baychelier, A. Sennepin, M. Ermonval, K. Dorgham, P. Debre et al., Identification of a cellular ligand for the natural cytotoxicity receptor NKp44, Blood, vol.122, issue.17, pp.2935-2977, 2013.
DOI : 10.1182/blood-2013-03-489054

F. Damm, T. Oberacker, F. Thol, E. Surdziel, K. Wagner et al., Expression in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.6, pp.682-691, 2011.
DOI : 10.1200/JCO.2010.31.1118

F. Thoren, A. Romero, and K. Hellstrand, Oxygen Radicals Induce Poly(ADP-Ribose) Polymerase-Dependent Cell Death in Cytotoxic Lymphocytes, The Journal of Immunology, vol.176, issue.12, pp.7301-7308, 2006.
DOI : 10.4049/jimmunol.176.12.7301

J. Aurelius, F. Thoren, A. Akhiani, M. Brune, L. Palmqvist et al., Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis, Blood, vol.119, issue.24, pp.5832-5839, 2012.
DOI : 10.1182/blood-2011-11-391722

F. Pucci and M. Pittet, Molecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo, Clinical Cancer Research, vol.19, pp.2598-604, 2013.
DOI : 10.1158/1078-0432.CCR-12-0962

M. Szczepanski, M. Szajnik, A. Welsh, T. Whiteside, and M. Boyiadzis, Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-??1, Haematologica, vol.96, issue.9, pp.1302-1311, 2011.
DOI : 10.3324/haematol.2010.039743

M. Baj-krzyworzeka, R. Szatanek, K. Weglarczyk, J. Baran, and M. Zembala, Tumour-derived microvesicles modulate biological activity of human monocytes, Immunology Letters, vol.113, issue.2, pp.76-82, 2007.
DOI : 10.1016/j.imlet.2007.07.014

L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti et al., Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value., Blood, vol.110, issue.1, pp.433-473, 2007.
DOI : 10.1182/blood-2006-07-038687

L. Ruggeri, F. Aversa, M. Martelli, and A. Velardi, Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self, Immunological Reviews, vol.33, issue.1, pp.202-220, 2006.
DOI : 10.1182/blood-2001-12-0293

B. Savani, S. Mielke, S. Adams, M. Uribe, K. Rezvani et al., Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia, Leukemia, vol.174, issue.10, pp.2145-52, 2007.
DOI : 10.1046/j.1440-1711.1999.00865.x

J. Miller, Y. Soignier, A. Panoskaltsis-mortari, S. Mcnearney, G. Yun et al., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, vol.105, issue.8, pp.3051-3058, 2005.
DOI : 10.1182/blood-2004-07-2974

G. Suck, V. Oei, Y. Linn, S. Ho, S. Chu et al., Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies, Experimental Hematology, vol.39, issue.9, pp.904-918, 2011.
DOI : 10.1016/j.exphem.2011.06.003

C. Chan, D. Andrews, and M. Smyth, Can NK cells be a therapeutic target in human diseases?, European Journal of Immunology, vol.24, issue.11, pp.2964-2972, 2008.
DOI : 10.1002/eji.200838764

M. Brune, S. Castaigne, J. Catalano, K. Gehlsen, A. Ho et al., Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial, Blood, vol.108, issue.1, pp.88-96, 2006.
DOI : 10.1182/blood-2005-10-4073

M. Hansson, S. Hermodsson, M. Brune, U. Mellqvist, P. Naredi et al., Histamine Protects T Cells and Natural Killer Cells Against Oxidative Stress, Journal of Interferon & Cytokine Research, vol.19, issue.10, pp.1135-1179, 1999.
DOI : 10.1089/107999099313073

K. Hellstrand, A. Asea, and S. Hermodsson, Role of histamine in natural killer cellmediated resistance against tumor cells, J Immunol, vol.145, pp.4365-70, 1990.

K. Hellstrand and S. Hermodsson, Synergistic Activation of Human Natural Killer Cell Cytotoxicity by Histamine and lnterleukin-2, International Archives of Allergy and Immunology, vol.92, issue.4, pp.379-89, 1990.
DOI : 10.1159/000235169

A. Romero, F. Thoren, M. Brune, K. Hellstrand, L. Kopp et al., NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species, British Journal of Haematology, vol.4, issue.1, pp.91-8296, 2006.
DOI : 10.1189/jlb.0704387

K. Tang, C. He, G. Zeng, J. Wu, G. Song et al., Induction of MHC class I-related chain B (MICB) by 5-aza-2???-deoxycytidine, Biochemical and Biophysical Research Communications, vol.370, issue.4, pp.578-83, 2008.
DOI : 10.1016/j.bbrc.2008.03.131

S. Santourlidis, H. Trompeter, S. Weinhold, B. Eisermann, K. Meyer et al., Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK Cells, The Journal of Immunology, vol.169, issue.8, pp.4253-61, 2002.
DOI : 10.4049/jimmunol.169.8.4253

F. Davies, N. Raje, T. Hideshima, S. Lentzsch, G. Young et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, vol.98, issue.1, pp.210-216, 2001.
DOI : 10.1182/blood.V98.1.210

N. Reddy, F. Hernandez-ilizaliturri, G. Deeb, M. Roth, M. Vaughn et al., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in??vivo, British Journal of Haematology, vol.59, issue.39, pp.36-45, 2008.
DOI : 10.1182/blood-2005-07-2817

S. Berg, M. Cairo, H. Russell, J. Ayello, A. Ingle et al., Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report, Journal of Clinical Oncology, vol.29, issue.3, pp.316-339, 2011.
DOI : 10.1200/JCO.2010.30.8387

J. Shi, G. Tricot, T. Garg, P. Malaviarachchi, S. Szmania et al., Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma, Blood, vol.111, issue.3, pp.1309-1326, 2008.
DOI : 10.1182/blood-2007-03-078535

A. Soriani, A. Zingoni, C. Cerboni, M. Iannitto, M. Ricciardi et al., ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype, Blood, vol.113, issue.15, pp.3503-3514, 2008.
DOI : 10.1182/blood-2008-08-173914

E. Alici, IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers, Curr Opin Mol Ther, vol.12, pp.724-757, 2010.

N. Vey, J. Bourhis, N. Boissel, D. Bordessoule, T. Prebet et al., A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission, Blood, vol.120, issue.22, pp.4317-4340, 2012.
DOI : 10.1182/blood-2012-06-437558

D. Benson, . Jr, C. Hofmeister, S. Padmanabhan, A. Suvannasankha et al., A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma, Blood, vol.120, issue.22, pp.4324-4357, 2012.
DOI : 10.1182/blood-2012-06-438028

M. Wallace and M. Smyth, The role of natural killer cells in tumor control???effectors and regulators of adaptive immunity, Springer Seminars in Immunopathology, vol.27, issue.1, pp.49-64, 2005.
DOI : 10.1007/s00281-004-0195-x

J. Weitzman, M. Betancur, L. Boissel, A. Rabinowitz, A. Klein et al., Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.9, issue.10, pp.1361-1369, 2009.
DOI : 10.1038/leu.2008.15

G. Cartron, L. Dacheux, G. Salles, P. Solal-celigny, P. Bardos et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene, Blood, vol.99, issue.3, pp.754-762, 2002.
DOI : 10.1182/blood.V99.3.754

S. Treon, M. Hansen, A. Branagan, S. Verselis, C. Emmanouilides et al., Polymorphisms in Fc??RIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenstr??m???s Macroglobulinemia, Journal of Clinical Oncology, vol.23, issue.3, pp.474-81, 2005.
DOI : 10.1200/JCO.2005.06.059

A. Boltz, B. Piater, L. Toleikis, R. Guenther, H. Kolmar et al., Bi-specific Aptamers Mediating Tumor Cell Lysis, Journal of Biological Chemistry, vol.286, issue.24, pp.21896-905, 2011.
DOI : 10.1074/jbc.M111.238261
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122244

L. Markasz, H. Skribek, M. Uhlin, R. Otvos, E. Flaberg et al., Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes, Journal of Immunotherapy, vol.31, issue.3, pp.283-93, 2008.
DOI : 10.1097/CJI.0b013e3181628b76

A. Kittang, K. Hatfield, K. Sand, H. Reikvam, and O. Bruserud, The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in